VNA and PACS markets are expected to grow significantly from 2013 to 2018.
According to a report by global marketing research firm MarketsandMarkets, the global VNA and PACS markets will likely grow into a $3.48 billion industry by 2018..
Conducted by global marketing firm MarketsandMarkets, the report looked at vendor-neutral archvies (VNA), as well as PACS systems, in both radiology departments and enterprise endeavors. Currently, department-level PACS make up the majority of the market, producing 86.5 percent of all revenue.
Department-level PACS are considered to be the most mature facet of this market, meaning their projected growth will be stable, but moderate. Between 2013 and 2018, the report predicted a 5.2 percent compounded annual growth rate (CAGR). Enterprise PACS are expected to experience more significant growth, soaring to $510 million by 2018. Significant growth is also expected for VNAs – a rise from $165.3 million in 2013 to $335.4 million in 2018.
While North America claims the majority of the VNA and PACS markets, boasting 64 percent and 48 percent, respectively, the report anticipates international growth. Germany, France, and the United Kingdom are significant players in the European market; the Asian-Pacific region is expected to expand thanks to national and statewide healthcare IT policies in Australia, China, and Japan. There is also potential for VNA and PACS adoption in Latin America and the Middle East, according to MarketsandMarkets.
Study with CT Data Suggests Women with PE Have More Than Triple the One-Year Mortality Rate than Men
April 3rd 2025After a multivariable assessment including age and comorbidities, women with pulmonary embolism (PE) had a 48 percent higher risk of one-year mortality than men with PE, according to a new study involving over 33,000 patients.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.